Evidence map›Paper›PMID 42942247›Full record

ArticleLife (Basel, Switzerland)2026

Growth Differentiation Factor 15 Is Associated with Severe Coronary Artery Calcification in Patients with Chronic Kidney Disease.

Maria Kislikova, Paola Nova Montoya, Laura García García, José Antonio Parra Blanco, María Teresa García Unzueta, Vicente Celestino Pinera Haces, María de la Oliva Valentín Munoz, Adalberto Benito Hernández, Juan Carlos Ruiz San Millán, Emilio Rodrigo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria KislikovaImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.ORCID 0000-0002-8387-1607
Paola Nova MontoyaImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.
Laura García GarcíaImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.
José Antonio Parra BlancoRadiology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.
María Teresa García UnzuetaClinical Laboratory Department, Marqués de Valdecilla University Hospital-IDIVAL, 39008 Santander, Spain.ORCID 0000-0003-2531-3284
Vicente Celestino Pinera HacesImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.
María de la Oliva Valentín MunozImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.
Adalberto Benito HernándezImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.ORCID 0000-0002-8733-1878
Juan Carlos Ruiz San MillánImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.ORCID 0000-0002-7904-8730
Emilio RodrigoImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39008 Santander, Spain.ORCID 0000-0002-2845-5272

Funding

Instituto de Investigación Marqués de Valdecilla MTVAL 18/01Instituto de Investigación Marqués de Valdecilla NextVal 18/09Instituto de Investigación Marqués de Valdecilla TRANSVAL 18/01Instituto de Salud Carlos III RICORS2040 (ISCIII RD24/0004/0019)
6 · The paper itself

Abstract

Patients with chronic kidney disease (CKD) have a high burden of coronary artery calcification (CAC) and cardiovascular risk. GDF-15 is a stress-responsive biomarker linked to kidney dysfunction and adverse cardiovascular outcomes, but its relationship with CAC across CKD stages is incompletely characterized. We evaluated associations of GDF-15 with severe CAC and major adverse cardiovascular events (MACE). In this prospective observational study, 128 patients with CKD and no previous cardiovascular disease had baseline GDF-15, dp-ucMGP, high-sensitivity cardiac troponin I, and NT-proBNP measured; CAC was quantified by computed tomography in 127. Severe CAC was defined as Agatston score ≥ 400. Mean serum GDF-15 was 4.5 ± 3.4 ng/mL. GDF-15 discriminated severe CAC (AUC 0.728; 95% CI 0.642-0.804;

Indexed as

cardiovascular eventschronic kidney diseasecoronary artery calcificationgrowth differentiation factor-15matrix Gla protein

Identifiers

PMID42942247
PMCPMC13705942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.